BLBP-expression in astrocytes during experimental demyelination and in human multiple sclerosis lesions

Brain, Behavior, and Immunity

Volumn 25, Issue 8, 2011, Pages 1554-1568

  Kipp, M ^a,c   Gingele, S ^a   Pott, F ^a   Clarner, T ^a   van der Valk, P ^c   Denecke, B ^b   Gan, L ^b   Siffrin, V ^f   Zipp, F ^f   Dreher, W ^e   Baumgartner, W ^b   Pfeifenbring, S ^g   Godbout, R ^h   Amor, S ^c,d   Beyer, C ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF BREMEN   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Astroglia; Multiple sclerosis; Oligodendrocyte; Regeneration; Remyelination

Indexed keywords

BRAIN LIPID BINDING PROTEIN; CELL MARKER; CUPRIZONE; GROWTH FACTOR; LIPID BINDING PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOMA CELL; CELL ACTIVATION; CELLULAR STRESS RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE DURATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GLIA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATORY INFILTRATE; MALE; MOUSE; MULTIPLE SCLEROSIS; NERVE LESION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIAL NERVE; REMISSION; REMYELINIZATION; STEM CELL;

ADULT; AGED; ANIMALS; ASTROCYTES; BLOTTING, WESTERN; CARRIER PROTEINS; CELL COUNT; CELL LINE, TUMOR; CUPRIZONE; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FATTY ACID-BINDING PROTEINS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PLATELET-DERIVED GROWTH FACTOR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 80053929393     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.05.003     Document Type: Article

References (84)

1. Acs P., Kipp M., Norkute A., Johann S., Clarner T., Braun A., et al. 17beta-Estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 2009, 57:807-814.
2. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4:1116-1122.
3. Arnett H.A., Wang Y., Matsushima G.K., Suzuki K., Ting J.P. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J. Neurosci. 2003, 23:9824-9832.
4. Back S.A., Tuohy T.M., Chen H., Wallingford N., Craig A., Struve J., et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 2005, 11:966-972.
5. Baertling F., Kokozidou M., Pufe T., Clarner T., Windoffer R., Wruck C.J., et al. ADAM12 is expressed by astrocytes during experimental demyelination. Brain Res. 2010, 1326:1-14.
6. Balendiran G.K., Schnutgen F., Scapin G., Borchers T., Xhong N., Lim K., et al. Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J. Biol. Chem. 2000, 275:27045-27054.
7. Bannerman P., Hahn A., Soulika A., Gallo V., Pleasure D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 2007, 55:57-64.
8. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 2006, 15:2813-2824.
9. Barry D., McDermott K. Differentiation of radial glia from radial precursor cells and transformation into astrocytes in the developing rat spinal cord. Glia 2005, 50:187-197.
10. Biancotti J.C., Kumar S., de Vellis J. Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. Neurochem. Res. 2008, 33:2615-2628.
11. Bibel M., Richter J., Schrenk K., Tucker K.L., Staiger V., Korte M., et al. Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat. Neurosci. 2004, 7:1003-1009.
12. Braun A., Dang J., Johann S., Beyer C., Kipp M. Selective regulation of growth factor expression in cultured cortical astrocytes by neuro-pathological toxins. Neurochem. Int. 2009, 55:610-618.
13. Chang A., Nishiyama A., Peterson J., Prineas J., Trapp B.D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 2000, 20:6404-6412.
14. Chang A., Tourtellotte W.W., Rudick R., Trapp B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 2002, 346:165-173.
15. Charles P., Reynolds R., Seilhean D., Rougon G., Aigrot M.S., Niezgoda A., et al. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis?. Brain 2002, 125:1972-1979.
16. Cimino P.J., Sokal I., Leverenz J., Fukui Y., Montine T.J. DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. Am. J. Pathol. 2009, 175:1622-1630.
17. Clarner T., Buschmann J.P., Beyer C., Kipp M. Glial amyloid precursor protein expression is restricted to astrocytes in an experimental toxic model of multiple sclerosis. J. Mol. Neurosci. 2011, 43:268-274.
18. Duplus E., Glorian M., Forest C. Fatty acid regulation of gene transcription. J. Biol. Chem. 2000, 275:30749-30752.
19. Fawcett J.W., Housden E., Smith-Thomas L., Meyer R.L. The growth of axons in three-dimensional astrocyte cultures. Dev. Biol. 1989, 135:449-458.
20. Geurts J.J., Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008, 7:841-851.
21. Goldschmidt T., Antel J., Konig F.B., Bruck W., Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009, 72:1914-1921.
22. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39:1083-1091.
23. Groebe A., Clarner T., Baumgartner W., Dang J., Beyer C., Kipp M. Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 2009, 8:163-174.
24. Halliday A.M. Visual evoked potentials in demyelinating disease. Adv. Neurol. 1981, 31:201-215.
25. Harsan L.A., Steibel J., Zaremba A., Agin A., Sapin R., Poulet P., et al. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J. Neurosci. 2008, 28:14189-14201.
26. Hashimoto M., Hossain S., Yamasaki H., Yazawa K., Masumura S. Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids 1999, 34:1297-1304.
27. Hesse A., Wagner M., Held J., Bruck W., Salinas-Riester G., Hao Z., et al. In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. Neurobiol. Dis. 2010, 37:362-369.
28. Hinks G.L., Franklin R.J. Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-beta1 gene expression during remyelination of experimentally-induced spinal cord demyelination. Mol. Cell. Neurosci. 1999, 14:153-168.
29. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
30. Irvine K.A., Blakemore W.F. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008, 131:1464-1477.
31. Johann S., Kampmann E., Denecke B., Arnold S., Kipp M., Mey J., et al. Expression of enzymes involved in the prostanoid metabolism by cortical astrocytes after LPS-induced inflammation. J. Mol. Neurosci. 2008, 34:177-185.
32. John G.R., Shankar S.L., Shafit-Zagardo B., Massimi A., Lee S.C., Raine C.S., et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat. Med. 2002, 8:1115-1121.
33. Kaloshi G., Mokhtari K., Carpentier C., Taillibert S., Lejeune J., Marie Y., et al. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J. Neurooncol. 2007, 84:245-248.
34. Kipp M., Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front. Neuroendocrinol. 2009, 30:188-200.
35. Kipp M., Norkute A., Johann S., Lorenz L., Braun A., Hieble A., et al. Brain-region-specific astroglial responses in vitro after LPS exposure. J. Mol. Neurosci. 2008, 35:235-243.
36. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009, 118:723-736.
37. Komoly S., Hudson L.D., Webster H.D., Bondy C.A. Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc. Natl. Acad. Sci. USA 1992, 89:1894-1898.
38. Kotter M.R., Li W.W., Zhao C., Franklin R.J. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci. 2006, 26:328-332.
39. Kuhlmann T., Miron V., Cui Q., Wegner C., Antel J., Bruck W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008, 131:1749-1758.
40. Liang Y., Bollen A.W., Aldape K.D., Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 2006, 6:97.
41. Lindner M., Fokuhl J., Linsmeier F., Trebst C., Stangel M. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci. Lett. 2009, 453:120-125.
42. Liu Y., Hao W., Letiembre M., Walter S., Kulanga M., Neumann H., et al. Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J. Neurosci. 2006, 26:12904-12913.
43. Liu L., Darnall L., Hu T., Choi K., Lane T.E., Ransohoff R.M. Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells. J. Neurosci. 2010, 30:9074-9083.
44. Ludwin S.K. Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity. Lab. Invest. 1978, 39:597-612.
45. Ma D., Zhang M., Mori Y., Yao C., Larsen C.P., Yamashima T., et al. Cellular localization of epidermal-type and brain-type fatty acid-binding proteins in adult hippocampus and their response to cerebral ischemia. Hippocampus 2009.
46. Maere S., Heymans K., Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005, 21:3448-3449.
47. Mana P., Linares D., Fordham S., Staykova M., Willenborg D. Deleterious role of IFNgamma in a toxic model of central nervous system demyelination. Am. J. Pathol. 2006, 168:1464-1473.
48. Mason J.L., Suzuki K., Chaplin D.D., Matsushima G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 2001, 21:7046-7052.
49. Mason J.L., Xuan S., Dragatsis I., Efstratiadis A., Goldman J.E. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J. Neurosci. 2003, 23:7710-7718.
50. Messersmith D.J., Murtie J.C., Le T.Q., Frost E.E., Armstrong R.C. Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination. J. Neurosci. Res. 2000, 62:241-256.
51. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
52. Mildner A., Schmidt H., Nitsche M., Merkler D., Hanisch U.K., Mack M., et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 2007, 10:1544-1553.
53. Miron V.E., Zehntner S.P., Kuhlmann T., Ludwin S.K., Owens T., Kennedy T.E., et al. Statin therapy inhibits remyelination in the central nervous system. Am. J. Pathol. 2009, 174:1880-1890.
54. Mita R., Coles J.E., Glubrecht D.D., Sung R., Sun X., Godbout R. B-FABP-expressing radial glial cells: the malignant glioma cell of origin?. Neoplasia 2007, 9:734-744.
55. Mita R., Beaulieu M.J., Field C., Godbout R. Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration. J. Biol. Chem. 2010, 285:37005-37015.
56. Moharregh-Khiabani D., Blank A., Skripuletz T., Miller E., Kotsiari A., Gudi V., et al. Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS ONE 2010, 5:e11769.
57. Mosley K., Cuzner M.L. Receptor-mediated phagocytosis of myelin by macrophages and microglia: effect of opsonization and receptor blocking agents. Neurochem. Res. 1996, 21:481-487.
58. Njenga M.K., Murray P.D., McGavern D., Lin X., Drescher K.M., Rodriguez M. Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler's virus. J. Neuropathol. Exp. Neurol. 1999, 58:78-91.
59. Norkute A., Hieble A., Braun A., Johann S., Clarner T., Baumgartner W., et al. Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J. Neurosci. Res. 2009, 87:1343-1355.
60. Patani R., Balaratnam M., Vora A., Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol. Appl. Neurobiol. 2007, 33:277-287.
61. Patrikios P., Stadelmann C., Kutzelnigg A., Rauschka H., Schmidbauer M., Laursen H., et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-3172.
62. Perier O., Gregoire A. Electron microscopic features of multiple sclerosis lesions. Brain 1965, 88:937-952.
63. Prineas J.W., Connell F. Remyelination in multiple sclerosis. Ann. Neurol. 1979, 5:22-31.
64. Rist J.M., Franklin R.J. Taking ageing into account in remyelination-based therapies for multiple sclerosis. J. Neurol. Sci. 2008, 274:64-67.
65. Rojas C.V., Martinez J.I., Flores I., Hoffman D.R., Uauy R. Gene expression analysis in human fetal retinal explants treated with docosahexaenoic acid. Invest. Ophthalmol. Vis. Sci. 2003, 44:3170-3177.
66. Sabo J.K., Aumann T.D., Merlo D., Kilpatrick T.J., Cate H.S. Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions. J. Neurosci. 2011, 31:4504-4510.
67. Schmid R.S., Yokota Y., Anton E.S. Generation and characterization of brain lipid-binding protein promoter-based transgenic mouse models for the study of radial glia. Glia 2006, 53:345-351.
68. Scolding N., Franklin R., Stevens S., Heldin C.H., Compston A., Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 1998, 121(Pt 12):2221-2228.
69. Selvaraju R., Bernasconi L., Losberger C., Graber P., Kadi L., Avellana-Adalid V., et al. Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro. Mol. Cell. Neurosci. 2004, 25:707-721.
70. Shen S., Sandoval J., Swiss V.A., Li J., Dupree J., Franklin R.J., et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 2008, 11:1024-1034.
71. Shields S.A., Gilson J.M., Blakemore W.F., Franklin R.J. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. Glia 1999, 28:77-83.
72. Shum B.O., Mackay C.R., Gorgun C.Z., Frost M.J., Kumar R.K., Hotamisligil G.S., et al. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J. Clin. Invest. 2006, 116:2183-2192.
73. Sibbe M., Forster E., Basak O., Taylor V., Frotscher M. Reelin and Notch1 cooperate in the development of the dentate gyrus. J. Neurosci. 2009, 29:8578-8585.
74. Stegbauer J., Lee D.H., Seubert S., Ellrichmann G., Manzel A., Kvakan H., et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. USA 2009, 106:14942-14947.
75. Stillwell W., Wassall S.R. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem. Phys. Lipids 2003, 126:1-27.
76. van der Valk P., De Groot C.J. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol. Appl. Neurobiol. 2000, 26:2-10.
77. Vana A.C., Flint N.C., Harwood N.E., Le T.Q., Fruttiger M., Armstrong R.C. Platelet-derived growth factor promotes repair of chronically demyelinated white matter. J. Neuropathol. Exp. Neurol. 2007, 66:975-988.
78. Veerkamp J.H., Zimmerman A.W. Fatty acid-binding proteins of nervous tissue. J. Mol. Neurosci. 2001, 16:133-142. discussion 51-57.
79. Watanabe A., Toyota T., Owada Y., Hayashi T., Iwayama Y., Matsumata M., et al. Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype. PLoS Biol. 2007, 5:e297.
80. Williams K., Ulvestad E., Waage A., Antel J.P., McLaurin J. Activation of adult human derived microglia by myelin phagocytosis in vitro. J. Neurosci. Res. 1994, 38:433-443.
81. Williams A., Piaton G., Lubetzki C. Astrocytes-friends or foes in multiple sclerosis?. Glia 2007, 55:1300-1312.
82. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 1998, 18:601-609.
83. Woodruff R.H., Fruttiger M., Richardson W.D., Franklin R.J. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol. Cell. Neurosci. 2004, 25:252-262.
84. Zimmerman A.W., Veerkamp J.H. New insights into the structure and function of fatty acid-binding proteins. Cell. Mol. Life Sci. 2002, 59:1096-1116.